The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice

Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucle...

Full description

Saved in:
Bibliographic Details
Published inPsychopharmacologia Vol. 167; no. 3; pp. 257 - 264
Main Authors Paterson, Neil E., Semenova, Svetlana, Gasparini, Fabrizio, Markou, Athina
Format Journal Article
LanguageEnglish
Published Berlin Springer 01.05.2003
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0033-3158
1432-2072
DOI10.1007/s00213-003-1432-z

Cover

Abstract Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine. The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice. Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 microg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair. MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 microg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice. These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission.
AbstractList Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine.RATIONALENicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine.The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice.OBJECTIVESThe present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice.Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 microg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair.METHODSRats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 microg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair.MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 microg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice.RESULTSMPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 microg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice.These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission.CONCLUSIONSThese results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission.
Rationale. Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine. Objectives. The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice. Methods. Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 μg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair. Results. MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 μg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice. Conclusions. These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission.
Rationale. Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine.Objectives. The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA /2J mice.Methods. Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 mu g per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair.Results. MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 mu g per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice.Conclusions. These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission.
Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine. The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice. Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 microg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair. MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 microg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice. These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission.
Author Markou, Athina
Semenova, Svetlana
Paterson, Neil E.
Gasparini, Fabrizio
Author_xml – sequence: 1
  givenname: Neil E.
  surname: Paterson
  fullname: Paterson, Neil E.
– sequence: 2
  givenname: Svetlana
  surname: Semenova
  fullname: Semenova, Svetlana
– sequence: 3
  givenname: Fabrizio
  surname: Gasparini
  fullname: Gasparini, Fabrizio
– sequence: 4
  givenname: Athina
  surname: Markou
  fullname: Markou, Athina
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14862478$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/12682710$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtLxDAUhYMoOj5-gBsJgu6qebVJlyK-QHEYdB1icquRNtWkXeivN-OMCoKYLHIh37nce84mWg19AIR2KTmihMjjRAijvCCEF1RwVryvoMlnwYhkq2iSP3jBaak20GZKzyQfocQ62qCsUkxSMkGzuyfA3UU7zkpswmAe--DTgG-mZ1PswEYwCRwO3vaDD4ATtE1hXOfnVDSD7wP2AecqZbnDnbewjdYa0ybYWb5b6P787O70sri-vbg6PbkuLFflUEglmKgFAWYqWjOXZ25cU3HJObWUg3M1r21Vy3ytNRZc-eCsbVRTy0ooxbfQ4aLvS-xfR0iD7nyy0LYmQD8mLTmTlaLkX5AqWbLMZXD_F_jcjzHkJTSjqi6loFWG9pbQ-NCB0y_Rdya-6S9PM3CwBEyypm2iCdanH06oigk5n18uOBv7lCI02vrh09LsrG81JXqesl6krHOYeh6ufs9K-kv53fxPzQdtPadB
CODEN PSYPAG
CitedBy_id crossref_primary_10_1038_tp_2016_132
crossref_primary_10_1016_j_biopsych_2020_06_020
crossref_primary_10_1016_j_ejphar_2010_01_029
crossref_primary_10_1007_s00213_010_2095_1
crossref_primary_10_1016_j_bcp_2013_07_007
crossref_primary_10_1016_j_neuropharm_2005_06_007
crossref_primary_10_1016_j_bmcl_2006_04_032
crossref_primary_10_1016_j_pbb_2014_09_020
crossref_primary_10_1016_j_bbr_2012_01_042
crossref_primary_10_1002_wmts_18
crossref_primary_10_1021_jm070078r
crossref_primary_10_1016_j_bmcl_2011_04_047
crossref_primary_10_1097_01_ALC_0000093601_33119_E3
crossref_primary_10_1016_j_neulet_2008_12_028
crossref_primary_10_1016_j_neuropharm_2011_08_028
crossref_primary_10_1016_j_drugalcdep_2008_09_006
crossref_primary_10_1038_nrn2515
crossref_primary_10_1038_aps_2014_93
crossref_primary_10_1039_c0ob01190h
crossref_primary_10_1021_jm050570f
crossref_primary_10_1007_s00213_015_4056_1
crossref_primary_10_1111_j_1749_6632_2011_06415_x
crossref_primary_10_1016_j_brainresbull_2015_11_010
crossref_primary_10_1007_s00213_004_2069_2
crossref_primary_10_1016_j_conb_2013_02_013
crossref_primary_10_1038_aps_2009_46
crossref_primary_10_1016_j_biopsych_2020_02_017
crossref_primary_10_1007_s00213_010_1950_4
crossref_primary_10_1016_j_tips_2003_11_003
crossref_primary_10_1517_13543776_18_2_123
crossref_primary_10_1007_s00213_011_2189_4
crossref_primary_10_1097_WNR_0b013e3283021cc0
crossref_primary_10_1586_ecp_09_6
crossref_primary_10_1196_annals_1441_015
crossref_primary_10_1093_cercor_bhi087
crossref_primary_10_1016_j_bmcl_2007_03_066
crossref_primary_10_1016_j_ejphar_2007_06_003
crossref_primary_10_1016_j_drugalcdep_2011_11_002
crossref_primary_10_1016_j_tips_2004_03_009
crossref_primary_10_1111_j_1369_1600_2010_00235_x
crossref_primary_10_1111_j_1460_9568_2005_03945_x
crossref_primary_10_1007_s00213_010_1868_x
crossref_primary_10_1016_j_pbb_2010_12_023
crossref_primary_10_1016_j_pharmthera_2013_12_012
crossref_primary_10_1016_j_biopsych_2010_01_005
crossref_primary_10_1016_j_lfs_2011_09_014
crossref_primary_10_1007_s00213_005_0163_8
crossref_primary_10_1016_j_ejphar_2004_07_056
crossref_primary_10_1016_j_neuropharm_2006_10_003
crossref_primary_10_1016_j_pharmthera_2009_11_002
crossref_primary_10_1038_npp_2008_140
crossref_primary_10_1093_alcalc_agh200
crossref_primary_10_1007_s00213_022_06266_7
crossref_primary_10_1016_j_tips_2005_04_005
crossref_primary_10_1017_S1461145707007845
crossref_primary_10_1016_j_alcohol_2007_11_001
crossref_primary_10_1017_S1461145709991064
crossref_primary_10_1111_j_1471_4159_2004_02920_x
crossref_primary_10_1007_s00213_016_4220_2
crossref_primary_10_1124_jpet_103_052027
crossref_primary_10_1016_j_neuropharm_2009_10_001
crossref_primary_10_1038_sj_npp_1300845
crossref_primary_10_1016_j_bcp_2011_06_026
crossref_primary_10_1016_j_brainres_2007_10_007
crossref_primary_10_1016_j_biopsych_2009_09_016
crossref_primary_10_1093_ijnp_pyac034
crossref_primary_10_1016_j_neubiorev_2005_04_016
crossref_primary_10_1097_FBP_0b013e32832c7083
crossref_primary_10_1007_s00213_009_1479_6
crossref_primary_10_1016_j_neuropharm_2013_05_042
crossref_primary_10_1016_j_pbb_2011_03_015
crossref_primary_10_1007_s00213_005_0217_y
crossref_primary_10_3390_toxics8040095
crossref_primary_10_1016_j_bmcl_2006_12_083
crossref_primary_10_1016_j_neubiorev_2015_07_010
crossref_primary_10_1177_0269881110367460
crossref_primary_10_1007_s00259_015_3301_5
crossref_primary_10_1016_j_neuropharm_2011_05_012
crossref_primary_10_1146_annurev_neuro_061010_113734
crossref_primary_10_1196_annals_1316_061
crossref_primary_10_1124_jpet_109_151357
crossref_primary_10_1016_j_ejphar_2007_01_046
crossref_primary_10_1007_s00213_007_0755_6
crossref_primary_10_1016_j_bbr_2010_12_024
crossref_primary_10_1097_FBP_0b013e3282f18d58
crossref_primary_10_1196_annals_1300_040
crossref_primary_10_1080_17460441_2018_1458090
crossref_primary_10_1016_j_bcp_2007_07_031
crossref_primary_10_1016_j_ddstr_2006_10_018
crossref_primary_10_1016_j_ejphar_2008_06_081
crossref_primary_10_1038_npp_2011_103
crossref_primary_10_1124_jpet_104_076406
crossref_primary_10_1016_j_biopsych_2006_03_053
crossref_primary_10_1007_s00213_015_4179_4
crossref_primary_10_1021_acschemneuro_8b00601
crossref_primary_10_1134_S0022093020060010
crossref_primary_10_1016_j_drugalcdep_2013_08_024
crossref_primary_10_1017_S1461145708009450
crossref_primary_10_1007_s00213_008_1069_z
crossref_primary_10_1016_j_biopsych_2015_02_027
crossref_primary_10_1017_S1092852920001704
crossref_primary_10_1016_j_neuropharm_2006_05_005
crossref_primary_10_1038_npp_2008_50
crossref_primary_10_1016_j_bcp_2007_07_021
crossref_primary_10_1016_j_ejphar_2006_10_011
crossref_primary_10_1073_pnas_1210984110
crossref_primary_10_1111_j_1471_4159_2007_04818_x
crossref_primary_10_1177_24705470231154842
crossref_primary_10_1124_jpet_105_090449
crossref_primary_10_1007_s00213_005_0155_8
crossref_primary_10_1007_s00213_004_2067_4
crossref_primary_10_3389_fnins_2015_00404
crossref_primary_10_1016_j_biopsych_2018_03_001
crossref_primary_10_1038_sj_npp_1300381
crossref_primary_10_1196_annals_1432_034
crossref_primary_10_1007_BF03033479
crossref_primary_10_1038_sj_npp_1301477
crossref_primary_10_1016_j_euroneuro_2008_05_004
crossref_primary_10_1016_j_bcp_2007_05_020
crossref_primary_10_1038_sj_npp_1300417
crossref_primary_10_1007_s00213_016_4487_3
crossref_primary_10_1016_j_neuropharm_2004_07_025
crossref_primary_10_2165_00023210_200822090_00001
crossref_primary_10_1016_j_neuropharm_2006_07_023
crossref_primary_10_3349_ymj_2008_49_2_175
crossref_primary_10_1124_mol_104_003319
crossref_primary_10_1007_s00213_004_2070_9
crossref_primary_10_1017_S1461145708008584
crossref_primary_10_1016_j_brainresbull_2012_01_010
crossref_primary_10_1016_j_devbrainres_2003_09_010
crossref_primary_10_1371_journal_pone_0024049
crossref_primary_10_1016_j_neubiorev_2015_06_004
crossref_primary_10_1111_j_1530_0277_2007_00570_x
crossref_primary_10_1007_s00213_011_2578_8
crossref_primary_10_1007_s00213_006_0583_0
crossref_primary_10_1038_sj_npp_1301623
crossref_primary_10_1016_j_drugalcdep_2006_04_003
crossref_primary_10_1016_j_biopsych_2018_02_009
crossref_primary_10_1016_j_pharmthera_2007_04_007
crossref_primary_10_1016_j_neuropharm_2012_08_006
crossref_primary_10_1016_j_neuropharm_2023_109694
crossref_primary_10_1016_j_ejphar_2008_12_042
crossref_primary_10_1111_j_1369_1600_2010_00246_x
crossref_primary_10_4103_0019_5545_33253
crossref_primary_10_1177_02698811241292902
crossref_primary_10_1176_foc_5_2_foc208
crossref_primary_10_1016_S1359_6446_03_02890_3
crossref_primary_10_1098_rstb_2008_0095
crossref_primary_10_1016_j_pbb_2008_02_002
crossref_primary_10_1176_appi_ajp_162_8_1403
crossref_primary_10_1007_s00213_012_2837_3
crossref_primary_10_1038_mp_2013_51
crossref_primary_10_1111_j_1527_3458_2006_00149_x
crossref_primary_10_1016_j_ejphar_2003_11_068
crossref_primary_10_1016_j_neuint_2005_08_010
crossref_primary_10_1016_S0014_2999_03_01904_6
crossref_primary_10_1016_j_bcp_2007_06_039
crossref_primary_10_1007_s00213_008_1144_5
crossref_primary_10_1002_syn_10242
crossref_primary_10_1016_j_biopsych_2017_11_021
crossref_primary_10_1016_j_ejphar_2009_01_049
crossref_primary_10_1038_nrn1298
crossref_primary_10_1007_s00213_007_0753_8
crossref_primary_10_1007_s00213_005_2175_9
crossref_primary_10_1080_13556210500223272
crossref_primary_10_1371_journal_pone_0041824
crossref_primary_10_1124_pharmrev_121_000540
crossref_primary_10_3181_0712_MR_355
crossref_primary_10_3389_fphar_2014_00158
Cites_doi 10.1523/JNEUROSCI.22-13-05669.2002
10.1016/0091-3057(89)90483-8
10.1093/alcalc/37.5.495
10.1523/JNEUROSCI.22-07-02977.2002
10.1126/science.7569895
10.1016/0304-3940(93)90227-C
10.1038/nn0901-873
10.1016/S0031-6997(24)01492-3
10.1016/S0014-2999(00)00697-X
10.1016/0091-3057(93)90493-D
10.1016/S0006-8993(97)01141-4
10.1016/0006-8993(90)90431-A
10.1016/S0306-4530(97)00027-9
10.1002/(SICI)1098-2396(199901)31:1<76::AID-SYN10>3.0.CO;2-Y
10.1016/S0924-977X(97)00087-4
10.1016/S0022-3565(24)39029-9
10.1046/j.1471-4159.2000.0750889.x
10.1080/14622200050011277
10.1111/j.1749-6632.2001.tb03560.x
10.1146/annurev.pharmtox.37.1.205
10.1046/j.0953-816x.2001.01584.x
10.1016/S0896-6273(02)00625-6
10.1016/0006-8993(93)91461-Z
10.1016/0091-3057(94)00221-4
10.1016/S0165-6147(00)01694-1
10.1002/1098-2396(20001215)38:4<375::AID-SYN2>3.0.CO;2-Y
10.1016/0014-2999(95)00630-3
10.1016/S0924-977X(98)00025-X
10.1523/JNEUROSCI.22-09-03338.2002
10.1016/S0028-3908(01)00083-1
10.1016/S0091-3057(01)00548-2
10.1046/j.1471-4159.1999.0720157.x
10.1016/S0022-3565(24)29296-X
10.1016/S0014-2999(99)00431-8
10.1037/0735-7044.112.6.1423
10.1016/S0028-3908(01)00036-3
10.1016/0091-3057(92)90382-P
10.1016/0924-977X(95)00066-X
10.1016/S0028-3908(02)00332-5
10.1016/S0149-7634(98)00055-4
10.1016/S0028-3908(99)00242-7
10.1007/BF02244174
10.1007/s00213-001-0953-6
10.1007/s002130000586
10.1523/JNEUROSCI.22-06-02135.2002
10.1006/mcne.2001.0992
10.1038/sj.bjp.0703923
10.1007/s002130050837
10.1016/S0166-4328(00)00311-9
10.1016/S0028-3908(99)00082-9
10.1016/S0014-2999(96)00961-2
10.1007/s00213-001-0965-2
10.1002/syn.10073
10.1002/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0.CO;2-D
10.1016/S0149-7634(98)00045-1
10.1097/00001756-199511270-00011
10.1080/14622200110073380
ContentType Journal Article
Copyright 2003 INIST-CNRS
Copyright Springer-Verlag 2003
Copyright_xml – notice: 2003 INIST-CNRS
– notice: Copyright Springer-Verlag 2003
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
88G
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
K9.
KB0
M0S
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1007/s00213-003-1432-z
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Animal Behavior Abstracts
Chemoreception Abstracts
Proquest Nursing & Allied Health Source
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
Technology Research Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Proquest Medical Database
Psychology Database (Proquest)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
Animal Behavior Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
ProQuest One Psychology
Animal Behavior Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-2072
EndPage 264
ExternalDocumentID 723535151
12682710
14862478
10_1007_s00213_003_1432_z
Genre Research Support, U.S. Gov't, P.H.S
Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: DA11946
– fundername: NIDA NIH HHS
  grantid: R56 DA011946
GroupedDBID .55
3SX
40D
40E
95.
95~
AAYXX
ABMNI
AGWIL
ALMA_UNASSIGNED_HOLDINGS
CITATION
KOW
N2Q
R9-
RHV
SBY
SOJ
X7M
~EX
IQODW
-4W
-BR
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GNUQQ
K9.
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
ID FETCH-LOGICAL-c385t-78424940e2a6192d207fdf637331c13edd939c697979ccaced5bdccf8f9764883
IEDL.DBID 7X7
ISSN 0033-3158
IngestDate Fri Jul 11 00:21:20 EDT 2025
Fri Jul 11 04:40:42 EDT 2025
Thu Aug 14 11:38:17 EDT 2025
Sat Sep 28 07:46:52 EDT 2024
Wed Apr 02 07:27:47 EDT 2025
Thu Jul 03 08:24:01 EDT 2025
Thu Apr 24 23:02:20 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Intraperitoneal administration
Intravenous administration
Rat
Self administration
Dose activity relation
Learning
Alkaloid
Acquisition process
Dependence
Reinforcement
Antagonist
Mechanism of action
Self-administration
mglu5 glutamate receptor
Poison withdrawal
Rodentia
Rats
Instrumental conditioning
MPEP
Biological activity
Vertebrata
Mammalia
Mouse
Animal
Mice
mGluR5
Nicotine
Language English
License http://www.springer.com/tdm
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c385t-78424940e2a6192d207fdf637331c13edd939c697979ccaced5bdccf8f9764883
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
PMID 12682710
PQID 218957416
PQPubID 47309
PageCount 8
ParticipantIDs proquest_miscellaneous_73276810
proquest_miscellaneous_18752103
proquest_journals_218957416
pubmed_primary_12682710
pascalfrancis_primary_14862478
crossref_citationtrail_10_1007_s00213_003_1432_z
crossref_primary_10_1007_s00213_003_1432_z
PublicationCentury 2000
PublicationDate 2003-05-01
PublicationDateYYYYMMDD 2003-05-01
PublicationDate_xml – month: 05
  year: 2003
  text: 2003-05-01
  day: 01
PublicationDecade 2000
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
– name: Germany
– name: Heidelberg
PublicationTitle Psychopharmacologia
PublicationTitleAlternate Psychopharmacology (Berl)
PublicationYear 2003
Publisher Springer
Springer Nature B.V
Publisher_xml – name: Springer
– name: Springer Nature B.V
References Battaglia (1432_CR1) 2001; 17
Spooren (1432_CR48) 2000; 406
File (1432_CR15) 1998; 112
Goeders (1432_CR18) 1997; 22
Goeders (1432_CR19) 1989; 33
Stolerman (1432_CR51) 1999; 141
Dewey (1432_CR13) 1999; 31
Semenova (1432_CR44) 1995; 50
Shaham (1432_CR46) 1992; 41
Sarnyai (1432_CR40) 2001; 53
Corrigall (1432_CR9) 1991; 104
David (1432_CR12) 2001; 13
Ramsay (1432_CR38) 1993; 608
Ossowska (1432_CR34) 2001; 41
Kuzmin (1432_CR25) 1996; 6
Gasparini (1432_CR16) 1999; 38
Vezina (1432_CR55) 1999; 23
Conn (1432_CR8) 1997; 37
Semenova (1432_CR45) 1999; 378
Kuzmin (1432_CR28) 1999; 9
Corrigall (1432_CR10) 2002; 160
Chiamulera (1432_CR7) 2001; 4
Caine (1432_CR4) 2002; 22
1432_CR22
Martellotta (1432_CR31) 1998; 8
Watkins (1432_CR56) 2000; 2
Miner (1432_CR33) 1995; 6
Spooren (1432_CR50) 2001; 22
Reid (1432_CR39) 2000; 35
Schulz (1432_CR43) 2001; 41
Picciotto (1432_CR37) 2002; 22
Breysse (1432_CR3) 2002; 22
Spooren (1432_CR49) 2000; 295
Schoepp (1432_CR42) 2001; 299
Zhang (1432_CR57) 2001; 937
Paterson (1432_CR35) 2002; 44
Piazza (1432_CR36) 1990; 514
Chapman (1432_CR6) 2000; 39
Holscher (1432_CR23) 2001; 23
Ghasemzadeh (1432_CR17) 1999; 72
Kuzmin (1432_CR26) 1996; 295
Schilstrom (1432_CR41) 2000; 38
Cossu (1432_CR11) 2001; 118
Irvine (1432_CR24) 2001; 153
Tatarczynska (1432_CR54) 2001; 132
Shigemoto (1432_CR47) 1993; 163
Harrison (1432_CR21) 2002; 160
Szyndler (1432_CR52) 2001; 69
Battaglia (1432_CR2) 2002; 22
Kuzmin (1432_CR27) 1997; 321
Cartmell (1432_CR5) 2000; 75
Tallaksen-Greene (1432_CR53) 1998; 780
McGehee (1432_CR32) 1995; 269
Markou (1432_CR30) 2001; 3
Goeders (1432_CR20) 1993; 44
Fattore (1432_CR14) 2002; 37
Mansvelder (1432_CR29) 2002; 33
11072438 - Nicotine Tob Res. 2000 Feb;2(1):19-37
7700949 - Pharmacol Biochem Behav. 1995 Jan;50(1):17-21
7569895 - Science. 1995 Sep 22;269(5231):1692-6
9926824 - Behav Neurosci. 1998 Dec;112(6):1423-9
11422457 - Eur J Neurosci. 2001 Jun;13(11):2157-64
11509211 - Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):511-8
11528416 - Nat Neurosci. 2001 Sep;4(9):873-4
11984860 - Synapse. 2002 Jun 15;44(4):252-3
11896153 - J Neurosci. 2002 Mar 15;22(6):2135-41
11414795 - Mol Cell Neurosci. 2001 Jun;17(6):1071-83
10854901 - Neuropharmacology. 2000 Jul 10;39(9):1567-74
8295733 - Neurosci Lett. 1993 Nov 26;163(1):53-7
12217945 - Alcohol Alcohol. 2002 Sep-Oct;37(5):495-8
8866940 - Eur Neuropsychopharmacol. 1996 Mar;6(1):63-8
11264235 - Br J Pharmacol. 2001 Apr;132(7):1423-30
10611638 - Synapse. 2000 Feb;35(2):129-36
11875638 - Psychopharmacology (Berl). 2002 Mar;160(2):198-205
11978809 - J Neurosci. 2002 May 1;22(9):3338-41
8495356 - Brain Res. 1993 Apr 16;608(2):216-22
10530811 - Neuropharmacology. 1999 Oct;38(10 ):1493-503
9989427 - Neurosci Biobehav Rev. 1999;23(3):399-410
10073895 - Neurosci Biobehav Rev. 1999 Mar;23(4):577-89
11082464 - J Pharmacol Exp Ther. 2000 Dec;295(3):1267-75
11445180 - Neuropharmacology. 2001 Jul;41(1):1-7
11163634 - Behav Brain Res. 2001 Jan 8;118(1):61-5
11923462 - J Neurosci. 2002 Apr 1;22(7):2977-88
2559416 - Pharmacol Biochem Behav. 1989 Aug;33(4):859-66
9928919 - Eur Neuropsychopharmacol. 1998 Dec;8(4):293-6
11040347 - Eur J Pharmacol. 2000 Oct 20;406(3):403-10
11561058 - J Pharmacol Exp Ther. 2001 Oct;299(1):12-20
11543761 - Neuropharmacology. 2001 Sep;41(4):413-20
11044884 - Synapse. 2000 Dec 15;38(4):375-83
9085036 - Eur J Pharmacol. 1997 Mar 5;321(3):265-71
10025686 - Synapse. 1999 Jan;31(1):76-86
11271403 - Psychopharmacology (Berl). 2001 Jan;153(3):315-20
1584842 - Pharmacol Biochem Behav. 1992 Mar;41(3):615-9
9131252 - Annu Rev Pharmacol Toxicol. 1997;37:205-37
10936169 - J Neurochem. 2000 Sep;75(3):889-907
8925870 - Eur J Pharmacol. 1996 Jan 4;295(1):19-25
12527469 - Neuropharmacology. 2002 Dec;43(8):1199-209
8446681 - Pharmacol Biochem Behav. 1993 Feb;44(2):471-4
11458542 - Ann N Y Acad Sci. 2001 Jun;937:93-120
9226728 - Psychoneuroendocrinology. 1997 May;22(4):237-59
9507137 - Brain Res. 1998 Jan 12;780(2):210-7
11694204 - Nicotine Tob Res. 2001 Nov;3(4):361-73
9886066 - J Neurochem. 1999 Jan;72(1):157-65
8747144 - Neuroreport. 1995 Nov 27;6(17):2314-6
10478558 - Eur J Pharmacol. 1999 Jul 28;378(1):1-8
1876661 - Psychopharmacology (Berl). 1991;104(2):171-6
11356984 - Pharmacol Rev. 2001 Jun;53(2):209-43
12097518 - J Neurosci. 2002 Jul 1;22(13):5669-78
11906697 - Neuron. 2002 Mar 14;33(6):905-19
10208288 - Eur Neuropsychopharmacol. 1999 Mar;9(3):197-203
11431019 - Trends Pharmacol Sci. 2001 Jul;22(7):331-7
2357527 - Brain Res. 1990 Apr 23;514(1):22-6
10027511 - Psychopharmacology (Berl). 1999 Jan;141(3):297-306
11862374 - Psychopharmacology (Berl). 2002 Feb;160(1):56-66
References_xml – volume: 22
  start-page: 5669
  year: 2002
  ident: 1432_CR3
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.22-13-05669.2002
– volume: 33
  start-page: 859
  year: 1989
  ident: 1432_CR19
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/0091-3057(89)90483-8
– volume: 37
  start-page: 495
  year: 2002
  ident: 1432_CR14
  publication-title: Alcohol Alcohol
  doi: 10.1093/alcalc/37.5.495
– volume: 22
  start-page: 2977
  year: 2002
  ident: 1432_CR4
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.22-07-02977.2002
– volume: 269
  start-page: 1692
  year: 1995
  ident: 1432_CR32
  publication-title: Science
  doi: 10.1126/science.7569895
– volume: 163
  start-page: 53
  year: 1993
  ident: 1432_CR47
  publication-title: Neurosci Lett
  doi: 10.1016/0304-3940(93)90227-C
– volume: 4
  start-page: 873
  year: 2001
  ident: 1432_CR7
  publication-title: Nature Neurosci
  doi: 10.1038/nn0901-873
– volume: 53
  start-page: 209
  year: 2001
  ident: 1432_CR40
  publication-title: Pharmacol Rev
  doi: 10.1016/S0031-6997(24)01492-3
– volume: 406
  start-page: 403
  year: 2000
  ident: 1432_CR48
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(00)00697-X
– volume: 44
  start-page: 471
  year: 1993
  ident: 1432_CR20
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/0091-3057(93)90493-D
– volume: 780
  start-page: 210
  year: 1998
  ident: 1432_CR53
  publication-title: Brain Res
  doi: 10.1016/S0006-8993(97)01141-4
– volume: 514
  start-page: 22
  year: 1990
  ident: 1432_CR36
  publication-title: Brain Res
  doi: 10.1016/0006-8993(90)90431-A
– volume: 22
  start-page: 237
  year: 1997
  ident: 1432_CR18
  publication-title: Psychoneuroendocrinology
  doi: 10.1016/S0306-4530(97)00027-9
– volume: 31
  start-page: 76
  year: 1999
  ident: 1432_CR13
  publication-title: Synapse
  doi: 10.1002/(SICI)1098-2396(199901)31:1<76::AID-SYN10>3.0.CO;2-Y
– volume: 8
  start-page: 293
  year: 1998
  ident: 1432_CR31
  publication-title: Eur Neuropsychopharmacol
  doi: 10.1016/S0924-977X(97)00087-4
– volume: 295
  start-page: 1267
  year: 2000
  ident: 1432_CR49
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(24)39029-9
– volume: 75
  start-page: 889
  year: 2000
  ident: 1432_CR5
  publication-title: J Neurochem
  doi: 10.1046/j.1471-4159.2000.0750889.x
– volume: 2
  start-page: 19
  year: 2000
  ident: 1432_CR56
  publication-title: Nicotine Tob Res
  doi: 10.1080/14622200050011277
– volume: 937
  start-page: 93
  year: 2001
  ident: 1432_CR57
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/j.1749-6632.2001.tb03560.x
– volume: 37
  start-page: 205
  year: 1997
  ident: 1432_CR8
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev.pharmtox.37.1.205
– volume: 13
  start-page: 2157
  year: 2001
  ident: 1432_CR12
  publication-title: Eur J Neurosci
  doi: 10.1046/j.0953-816x.2001.01584.x
– volume: 33
  start-page: 905
  year: 2002
  ident: 1432_CR29
  publication-title: Neuron
  doi: 10.1016/S0896-6273(02)00625-6
– volume: 608
  start-page: 216
  year: 1993
  ident: 1432_CR38
  publication-title: Brain Res
  doi: 10.1016/0006-8993(93)91461-Z
– volume: 50
  start-page: 17
  year: 1995
  ident: 1432_CR44
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/0091-3057(94)00221-4
– volume: 22
  start-page: 331
  year: 2001
  ident: 1432_CR50
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/S0165-6147(00)01694-1
– volume: 38
  start-page: 375
  year: 2000
  ident: 1432_CR41
  publication-title: Synapse
  doi: 10.1002/1098-2396(20001215)38:4<375::AID-SYN2>3.0.CO;2-Y
– volume: 295
  start-page: 19
  year: 1996
  ident: 1432_CR26
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(95)00630-3
– volume: 9
  start-page: 197
  year: 1999
  ident: 1432_CR28
  publication-title: Eur Neuropsychopharmacol
  doi: 10.1016/S0924-977X(98)00025-X
– volume: 22
  start-page: 3338
  year: 2002
  ident: 1432_CR37
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.22-09-03338.2002
– volume: 41
  start-page: 413
  year: 2001
  ident: 1432_CR34
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(01)00083-1
– volume: 69
  start-page: 511
  year: 2001
  ident: 1432_CR52
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/S0091-3057(01)00548-2
– volume: 72
  start-page: 157
  year: 1999
  ident: 1432_CR17
  publication-title: J Neurochem
  doi: 10.1046/j.1471-4159.1999.0720157.x
– volume: 299
  start-page: 12
  year: 2001
  ident: 1432_CR42
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(24)29296-X
– volume: 378
  start-page: 1
  year: 1999
  ident: 1432_CR45
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(99)00431-8
– volume: 112
  start-page: 1423
  year: 1998
  ident: 1432_CR15
  publication-title: Behav Neurosci
  doi: 10.1037/0735-7044.112.6.1423
– volume: 41
  start-page: 1
  year: 2001
  ident: 1432_CR43
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(01)00036-3
– volume: 41
  start-page: 615
  year: 1992
  ident: 1432_CR46
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/0091-3057(92)90382-P
– volume: 6
  start-page: 63
  year: 1996
  ident: 1432_CR25
  publication-title: Eur Neuropsychopharmacol
  doi: 10.1016/0924-977X(95)00066-X
– ident: 1432_CR22
  doi: 10.1016/S0028-3908(02)00332-5
– volume: 23
  start-page: 577
  year: 1999
  ident: 1432_CR55
  publication-title: Neurosci Biobehav Rev
  doi: 10.1016/S0149-7634(98)00055-4
– volume: 39
  start-page: 1567
  year: 2000
  ident: 1432_CR6
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(99)00242-7
– volume: 104
  start-page: 171
  year: 1991
  ident: 1432_CR9
  publication-title: Psychopharmacology
  doi: 10.1007/BF02244174
– volume: 160
  start-page: 56
  year: 2002
  ident: 1432_CR21
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-001-0953-6
– volume: 153
  start-page: 315
  year: 2001
  ident: 1432_CR24
  publication-title: Psychopharmacology
  doi: 10.1007/s002130000586
– volume: 22
  start-page: 2135
  year: 2002
  ident: 1432_CR2
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.22-06-02135.2002
– volume: 17
  start-page: 1071
  year: 2001
  ident: 1432_CR1
  publication-title: Mol Cell Neurosci
  doi: 10.1006/mcne.2001.0992
– volume: 132
  start-page: 1423
  year: 2001
  ident: 1432_CR54
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0703923
– volume: 141
  start-page: 297
  year: 1999
  ident: 1432_CR51
  publication-title: Psychopharmacology
  doi: 10.1007/s002130050837
– volume: 118
  start-page: 61
  year: 2001
  ident: 1432_CR11
  publication-title: Behav Brain Res
  doi: 10.1016/S0166-4328(00)00311-9
– volume: 38
  start-page: 1493
  year: 1999
  ident: 1432_CR16
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(99)00082-9
– volume: 321
  start-page: 265
  year: 1997
  ident: 1432_CR27
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(96)00961-2
– volume: 160
  start-page: 198
  year: 2002
  ident: 1432_CR10
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-001-0965-2
– volume: 44
  start-page: 252
  year: 2002
  ident: 1432_CR35
  publication-title: Synapse
  doi: 10.1002/syn.10073
– volume: 35
  start-page: 129
  year: 2000
  ident: 1432_CR39
  publication-title: Synapse
  doi: 10.1002/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0.CO;2-D
– volume: 23
  start-page: 399
  year: 2001
  ident: 1432_CR23
  publication-title: Neurosci Biobehav Rev
  doi: 10.1016/S0149-7634(98)00045-1
– volume: 6
  start-page: 2314
  year: 1995
  ident: 1432_CR33
  publication-title: Neuroreport
  doi: 10.1097/00001756-199511270-00011
– volume: 3
  start-page: 361
  year: 2001
  ident: 1432_CR30
  publication-title: Nicotine Tob Res
  doi: 10.1080/14622200110073380
– reference: 8495356 - Brain Res. 1993 Apr 16;608(2):216-22
– reference: 8866940 - Eur Neuropsychopharmacol. 1996 Mar;6(1):63-8
– reference: 11072438 - Nicotine Tob Res. 2000 Feb;2(1):19-37
– reference: 11422457 - Eur J Neurosci. 2001 Jun;13(11):2157-64
– reference: 11528416 - Nat Neurosci. 2001 Sep;4(9):873-4
– reference: 11082464 - J Pharmacol Exp Ther. 2000 Dec;295(3):1267-75
– reference: 11163634 - Behav Brain Res. 2001 Jan 8;118(1):61-5
– reference: 10025686 - Synapse. 1999 Jan;31(1):76-86
– reference: 11431019 - Trends Pharmacol Sci. 2001 Jul;22(7):331-7
– reference: 9928919 - Eur Neuropsychopharmacol. 1998 Dec;8(4):293-6
– reference: 9886066 - J Neurochem. 1999 Jan;72(1):157-65
– reference: 11862374 - Psychopharmacology (Berl). 2002 Feb;160(1):56-66
– reference: 10478558 - Eur J Pharmacol. 1999 Jul 28;378(1):1-8
– reference: 8295733 - Neurosci Lett. 1993 Nov 26;163(1):53-7
– reference: 7700949 - Pharmacol Biochem Behav. 1995 Jan;50(1):17-21
– reference: 11271403 - Psychopharmacology (Berl). 2001 Jan;153(3):315-20
– reference: 11978809 - J Neurosci. 2002 May 1;22(9):3338-41
– reference: 9085036 - Eur J Pharmacol. 1997 Mar 5;321(3):265-71
– reference: 11561058 - J Pharmacol Exp Ther. 2001 Oct;299(1):12-20
– reference: 12217945 - Alcohol Alcohol. 2002 Sep-Oct;37(5):495-8
– reference: 11044884 - Synapse. 2000 Dec 15;38(4):375-83
– reference: 2559416 - Pharmacol Biochem Behav. 1989 Aug;33(4):859-66
– reference: 1584842 - Pharmacol Biochem Behav. 1992 Mar;41(3):615-9
– reference: 11896153 - J Neurosci. 2002 Mar 15;22(6):2135-41
– reference: 11356984 - Pharmacol Rev. 2001 Jun;53(2):209-43
– reference: 11414795 - Mol Cell Neurosci. 2001 Jun;17(6):1071-83
– reference: 10936169 - J Neurochem. 2000 Sep;75(3):889-907
– reference: 11509211 - Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):511-8
– reference: 10208288 - Eur Neuropsychopharmacol. 1999 Mar;9(3):197-203
– reference: 8925870 - Eur J Pharmacol. 1996 Jan 4;295(1):19-25
– reference: 9226728 - Psychoneuroendocrinology. 1997 May;22(4):237-59
– reference: 10073895 - Neurosci Biobehav Rev. 1999 Mar;23(4):577-89
– reference: 2357527 - Brain Res. 1990 Apr 23;514(1):22-6
– reference: 7569895 - Science. 1995 Sep 22;269(5231):1692-6
– reference: 10854901 - Neuropharmacology. 2000 Jul 10;39(9):1567-74
– reference: 10027511 - Psychopharmacology (Berl). 1999 Jan;141(3):297-306
– reference: 1876661 - Psychopharmacology (Berl). 1991;104(2):171-6
– reference: 12527469 - Neuropharmacology. 2002 Dec;43(8):1199-209
– reference: 11923462 - J Neurosci. 2002 Apr 1;22(7):2977-88
– reference: 11458542 - Ann N Y Acad Sci. 2001 Jun;937:93-120
– reference: 11875638 - Psychopharmacology (Berl). 2002 Mar;160(2):198-205
– reference: 11984860 - Synapse. 2002 Jun 15;44(4):252-3
– reference: 11445180 - Neuropharmacology. 2001 Jul;41(1):1-7
– reference: 8747144 - Neuroreport. 1995 Nov 27;6(17):2314-6
– reference: 9507137 - Brain Res. 1998 Jan 12;780(2):210-7
– reference: 11264235 - Br J Pharmacol. 2001 Apr;132(7):1423-30
– reference: 8446681 - Pharmacol Biochem Behav. 1993 Feb;44(2):471-4
– reference: 11694204 - Nicotine Tob Res. 2001 Nov;3(4):361-73
– reference: 10611638 - Synapse. 2000 Feb;35(2):129-36
– reference: 11040347 - Eur J Pharmacol. 2000 Oct 20;406(3):403-10
– reference: 9131252 - Annu Rev Pharmacol Toxicol. 1997;37:205-37
– reference: 12097518 - J Neurosci. 2002 Jul 1;22(13):5669-78
– reference: 9926824 - Behav Neurosci. 1998 Dec;112(6):1423-9
– reference: 10530811 - Neuropharmacology. 1999 Oct;38(10 ):1493-503
– reference: 9989427 - Neurosci Biobehav Rev. 1999;23(3):399-410
– reference: 11906697 - Neuron. 2002 Mar 14;33(6):905-19
– reference: 11543761 - Neuropharmacology. 2001 Sep;41(4):413-20
SSID ssj0000484
ssj0068394
Score 2.2025964
Snippet Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic...
Rationale. Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 257
SubjectTerms Animals
Behavior, Animal - drug effects
Biological and medical sciences
Dose-Response Relationship, Drug
Drug Administration Routes - veterinary
Drug Administration Schedule - veterinary
Drug Interactions
Excitatory Amino Acid Antagonists - pharmacology
Feeding Behavior - drug effects
Male
Medical sciences
Mice
Mice, Inbred DBA
Nicotine - administration & dosage
Nicotinic Agonists - administration & dosage
Pyridines - pharmacology
Rats
Rats, Wistar
Receptor, Metabotropic Glutamate 5
Receptors, Metabotropic Glutamate - antagonists & inhibitors
Receptors, Metabotropic Glutamate - physiology
Reinforcement Schedule
Self Administration - methods
Self Administration - veterinary
Tobacco, tobacco smoking
Toxicology
Title The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice
URI https://www.ncbi.nlm.nih.gov/pubmed/12682710
https://www.proquest.com/docview/218957416
https://www.proquest.com/docview/18752103
https://www.proquest.com/docview/73276810
Volume 167
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swED62FsZgjK3bOq9dpofRh1Ex27Is-6k0W7IySDGhhbwZVz9KIXOyOXlo__rdyU5MHlr8YBtJltGdpO-k03cAX8NMu8i6nKvU5Jwo33gVauzuJtRO6FQbRwv6k8v04jr5PZOzzjen6dwqN2OiH6jNQtMa-XecinJJ8OFs-ZdT0CjaXO0iaDyHfc9chuqsZqofiBM6g9m-pAgEWkZmQefJZLbZ4Qw9oWhMMQ7ISwv_lj_szFGvllWDzeXaOBePA1E_IY3fwOsOSbLzVvRv4ZmtD-DFpNsrP4CTomWlvj9lV_0hq-aUnbCi56u-fwdTTGZ_fs3XU8mwnavbBbHpskkxKpjxqLKxhtWoMiv8MGvs3PFqh3OX3dUMnxosbhjFt38P1-PR1Y8L3oVa4FpkcsVVlqAdloQ2rsiiMnGonHGpoIiOOhLWmFzkOs0VXihzbY28MVq7zCGcwTFAfIC9elHbj8ASVZHVK12EyDLOo0prnSOOk1ZKhWA0gHDTuKXueMgpHMa83DIoe3kQa2lJ8igfAvi2LbJsSTieyjzYkVhfIqHDMCoL4GgjwrLrsE25Va8AvmxTsafR9klV28W6KSM07dBAFo_nUCJWxO8WwGGrGX3dcZrFCOY-PVn3Ebz0voLen_IY9lb_1vYzYp7VzcBr9gD2z4c_h2O8D0eXxfQ_CT_-TA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVAIkhKC8TKHdA_SAusL2ev04IMQjJaVNZEWp1Jtx94GQUifgRCj9T_xHZvyIlUN7q3yxZa9X9szOfrOz8w3AGzdW1jM24VGoE06Ubzx3FQ537SorVKi0pQX94SgcnAXfz-X5Fvxrc2FoW2VrEytDrWeK1sjf41SUSIIPH-e_ORWNouBqW0Gj1ooTs_qLHlv54fgrivet7x_1J18GvCkqwJWI5YJHcYAeR-AaPyffQftuZLUNBdUuVJ4wWiciUWES4YFfp4yWF1opG1ucuFHbBb73DmwHlNDag-3P_VE67kx_QFmf9UWI0KPmgBaUwSbjNqbqVhSmPlVVoH1h-H_41cas-GCelyggW1fWuB76VlPg0SN42GBX9qlWtsewZYoduDtsovM7cJDWPNirQzbp0rrKQ3bA0o4he_UExnibXX6bLseSoWTznzPi72XDtJ8yXeHY0mhWoJIu8MWsNFPL8w2WX_arYHhWYnPNLtHYPYWzW5HDM-gVs8K8ABZEOfnZ0nqIZf3Ey5VSCSJHaaSMEP464LY_N1MN8zkV4Jhma87mSh7Ek5qRPLIrB96tm8xr2o-bHt7bkFjXIqD0myh2YLcVYdaYiDJbK7QD--u7OLYpYJMXZrYsMw-dSXTJxfVPRMKPiFHOgee1ZnR9-2HsI3x8eWPf-3BvMBmeZqfHo5NduF_tVKx2c76C3uLP0rxGxLW42Gv0nMGP2x5a_wFJITlk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB9qhSKIaP2K1XYftA_S0GQ3m00eRMT2bK1XQmnh3tJ0P0S45k5zh1z_M_87Z_Jx4R7at5KXhGQTkpnZ-U125jcA74NEu9C61FexSX2ifPOLQKO5m0A7oWNtHP3QH57GRxfR95EcrcG_rhaG0iq7ObGeqM1E0z_yfXRFqST4sO_arIjsYPB5-tunBlK00Np102g05MQu_mL0Vn06PkBRf-B8cHj-9chvGwz4WiRy5qskwugjCiwvKI4wPFDOuFhQH0MdCmtMKlIdpwo3fFNtjbwyWrvEoRNHzRd43wfwUAkEVWhKaqR6JxBR_WdzECMIadigBdWyyaRbXQ1qMlNO_RUoQwy_lH-z4h8fT4sKReWaHhu3g-DaGQ6ewpMWxbIvjdo9gzVbbsLGsF2n34TdrGHEXuyx877Aq9pjuyzrubIXz-EMT7Prb-P5mWQo4-LnhJh82TA7zJipEW1lDStRXWd4Y1bZsfOLFb5f9qtkuFfhcMOucdp7ARf3IoWXsF5OSvsaWKQKirilCxHV8jQstNYpYkhppVQIhD0Iuo-b65YDnVpxjPMle3MtD2JMzUke-Y0HH5dDpg0ByF0Xb69IrB8RUSGOSjzY6kSYt5NFlS9V24Od5Vm0clq6KUo7mVd5iGElBufi9iuU4Iq45Tx41WhG_2weJxyB5Js7n70DG2hQ-Y_j05MteFSnLNZpnW9hffZnbt8h9JpdbddKzuDyvq3qP4y9PCs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+mGluR5+antagonist+MPEP+decreased+nicotine+self-administration+in+rats+and+mice&rft.jtitle=Psychopharmacology&rft.au=Paterson%2C+Neil+E.&rft.au=Semenova%2C+Svetlana&rft.au=Gasparini%2C+Fabrizio&rft.au=Markou%2C+Athina&rft.date=2003-05-01&rft.issn=0033-3158&rft.volume=167&rft.issue=3&rft.spage=257&rft.epage=264&rft_id=info:doi/10.1007%2Fs00213-003-1432-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00213_003_1432_z
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon